Navigation Links
/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
Date:9/2/2008

CALGARY, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr. Miguel Villalona-Calero, Professor Division of Hematology/Oncology and Department of Internal Medicine and Pharmacology at The Ohio State University Comprehensive Cancer Center.

"In this era of personalized cancer treatment, we are quite excited about this trial," said Dr. Villalona-Calero. "Although we have had for some time treatments that target EGFR, K-RAS has been an elusive target. REOLYSIN(R) has the potential to target K-RAS activated tumors, possibly enhancing the beneficial effects produced by chemotherapy."

"This trial gives Oncolytics the opportunity to treat NSCLC patients in a first-line clinical setting," said Dr. Brad Thompson, President and CEO of Oncolytics. "Assuming we achieve an acceptable response rate, the combination of REOLYSIN(R) with paclitaxel and carboplatin for NSCLC would be a strong candidate for registration studies."

This trial is a single arm, two-stage, open-label, Phase 2 study of REOLYSIN(R) given intravenously with paclitaxel and carboplatin every 3 weeks. Patients will receive four to six cycles of paclitaxel and carboplatin in conjunction with REOLYSIN(R), at which time REOLYSIN(R) may be continued as a monotherapy. It is anticipated that up to 36 patients will be treated in this trial.

Eligible patients include those with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, who have not received chemotherapy treatment for their metastatic or recurrent disease. Patients must have demonstrated mutations in K-RAS or EGFR, or EGFR
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
4. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
5. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
7. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
8. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
9. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2014)... (PRWEB) September 20, 2014 ... urological and interventional radiology products and services, has ... subsidiary with Clinicon Corporation for its ... HealthTronics’ portfolio of minimally invasive, mobile, surgical technology—offering ... , Under the agreement, HealthTronics will make available ...
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
(Date:9/19/2014)... Sept. 19, 2014 Pfenex Inc. (NYSE MKT: ... of high-value and difficult to manufacture proteins including biosimilar ... the 21 st Annual NewsMakers in the Biotech ... Bertrand Liang , chief executive officer of Pfenex, ... and business strategy on Friday, September 26, 2014 at ...
(Date:9/19/2014)... , September 19, 2014 ... 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... science and medical research in the field of growth  ... KGaA, Darmstadt, Germany , today announced ... (GGI) for 2014. The awards were announced during a ...
Breaking Biology Technology:HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3
... DUBLIN and PHILADELPHIA , July 8, 2010 ... global specialty biopharmaceutical company,announces that its subsidiaries Shire Development Inc. ... U.S. District,Court for the District of Delaware against ... ( USA ), Inc. (collectively,"Zydus") for the infringement of U.S. ...
... , CHICAGO , July 8 Advanced Life ... in the discovery, development and commercialization of novel drugs in the ... results from preclinical toxicology and pharmacokinetic studies of an intravenous (IV) ... a hospital setting. , , ...
... ... ... Oxford Performance Materials (OPM) is very pleased to announce that the firm’s OXPEKK-IG long-term ... KFDA approved the Viking interspinous spinal device made by OPM’s customer Sintea Plustek., , ...
Cached Biology Technology:Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc. 2Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc. 3Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use 2Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use 3Advanced Life Sciences Announces Successful Preclinical Data Supporting Restanza Intravenous Formulation for Hospital Use 4OXPEKK-IG Device Viking Gains Regulatory Approval in Korea 2OXPEKK-IG Device Viking Gains Regulatory Approval in Korea 3
(Date:9/19/2014)... a newly discovered hadrosaur with a truly ... Rhinorex condrupus by paleontologists from North Carolina ... what is now Utah approximately 75 million years ... which translates roughly into "King Nose," was a ... hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs are usually ...
(Date:9/19/2014)... of years has adapted to the arctic cold, and then ... dangerous for you. , This is happening to the small ... substance, called nonylphenol, comes from the use of certain detergents, ... endocrine disruptor, but when entering the worm it has another ... cells in its body from cold damage. , Enchytraeus ...
(Date:9/18/2014)... A sleep-promoting circuit located deep in the primitive ... Discovered by researchers at Harvard School of Medicine and ... Sciences, this is only the second "sleep node" identified ... both necessary and sufficient to produce deep sleep. , ... the study demonstrates that fully half of all of ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3No sedative necessary: Scientists discover new 'sleep node' in the brain 2
... it can damage blood vessels and increase the risk of ... he can thin the human blood by subjecting it to ... physics at Temple University, has pioneered the use of electric ... engines and pipelines. Now, he is using the same magnetic ...
... coastal areas in Africa can rarely utilise their entire fishing ... near the coast. Research carried out by economist Kofi Vondolia ... of fish stocks is significant to fish management. ... allows foreign fishing fleets to utilise the zones further out ...
... the Virginia Institute of Marine Science (VIMS) shows that jellyfish ... altering marine food webs by shunting food energy from fish ... frequency of jellyfish blooms in coastal and estuarine waters around ... impact on marine food webs is likely to increase into ...
Cached Biology News:Using magnets to help prevent heart attacks 2Optimum tax on foreign fishing in Africa protects stocks and domestic fishing 2Jellyfish blooms shunt food energy from fish to bacteria 2Jellyfish blooms shunt food energy from fish to bacteria 3